Cannara Biotech Inc. reports Q2 2023 Financial Results with quarterly net revenues of $13 million, a 76% increase compared to Q2 2022
Six-month net revenues of $23.4 million, a 67% increase compared to first half 2022
Delivered its eighth consecutive quarter of positive Adjusted EBITDA of $3.2M, a 1500% increase compared to Q2 2022
Related news for (LOVFF)
- Cannara Biotech Delivers Record Q2 Results as National Expansion Accelerates
- Cannara Biotech Inc. to Announce Fiscal Q2 2025 Financial Results on April 28, 2025
- Cannara Biotech Announces Appointment of Justin Cohen to Board of Directors
- Cannara Biotech to Present at The Ventum Canadian Cannabis Conference on March 12th, 2025
- Cannara Biotech Reports Record Q1 2025 Revenue and National Market Share, Sets Stage for Continued Momentum in 2025